Related Experiment Video
Updated: Dec 29, 2025
12:49
Porcine Liver Transplantation Without Veno-Venous Bypass As an Extended Criteria Donor Model
Published on: August 17, 2022
2.9K
Liver Xenotransplantation in a Nonhuman Primate Model
Nalú Navarro-Alvarez1,2,3, Parsia A Vagefi4
1Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Methods in Molecular Biology (Clifton, N.J.)
|February 1, 2020
Summary
Pig-to-baboon liver xenotransplantation (LXT) shows promise for overcoming donor shortages. Supplementing with human coagulation factors significantly improves survival by mitigating thrombocytopenia and thrombotic microangiopathy, key challenges in LXT.
Area of Science:
- Transplantation immunology
- Xenotransplantation research
- Surgical innovation
Background:
- Liver graft scarcity necessitates alternative solutions like xenotransplantation.
- Genetically engineered pigs (GalT-KO) address hyperacute rejection but not post-transplant complications.
- Severe thrombocytopenia and thrombotic microangiopathy (TMA) limit survival in liver xenotransplantation (LXT).
Purpose of the Study:
- To detail the technical procedure for pig-to-baboon liver xenotransplantation (LXT).
- To evaluate the efficacy of exogenous human coagulation factors in overcoming LXT-associated complications.
- To provide comprehensive peri- and postoperative care guidelines for LXT recipients.
Main Methods:
- Utilized genetically engineered alpha-1,3-galactosyltransferase knockout (GalT-KO) pigs for xenotransplantation.
- Administered exogenous human coagulation factors to recipients during and after LXT.
- Established a pig-to-baboon LXT model with detailed surgical and intensive care protocols.
Main Results:
- Exogenous human coagulation factors successfully mitigated severe thrombocytopenia and TMA post-LXT.
- Improved animal survival rates were observed following the administration of coagulation factors.
- The described technical procedure and care regimen facilitated successful LXT in the model.
Conclusions:
- Exogenous human coagulation factor administration is crucial for improving outcomes in pig-to-baboon LXT.
- Addressing coagulation barriers is essential for the clinical viability of liver xenotransplantation.
- This study provides a reproducible model and critical insights for advancing LXT.
